ZBIO Zenas Biopharma Inc.

$ZBIO - This stock is heading to $45 + . ZBIO has roughly a 65–75% chance of a positive SLE readout, based on encouraging prior clinical data and strong validation of obexelimab’s mechanism in other autoimmune diseases. A strong positive readout could be a major catalyst for ZBIO and will drive the stock price north of $45

$ZBIO - Based on the previous data and selective population there is very high probability that SLE data is going to be great and take this stock to $45+ range

Citi added $ZBIO (Buy-$48) to its Upside 90-Day Catalyst Watch List—believes the SunStone readout in systemic lupus erythematosus (SLE) in Q4 is well positioned to hit the primary endpoint.

$ZBIO Novartis calling its BTKinhibitor probably biggest ever drug... where will ZBIO trade if its own BTKinh reports positive P3 results? Lets see if safety holds up, that would be massive

$ZBIO 🏥 Zenas BioPharma, Inc. announced presentation of new Phase 3 INDIGO open-label extension data showing sustained clinical activity of obexelimab in IgG4-related disease, with fewer patients experiencing cumulative glucocorticoid toxicity at week 52. Curated for market relevance

$ZBIO plans to showcase seven MS posters and a BTK-inhibition symposium at MSToronto2026.